Alimera Sciences Inc Revenue Growth Rates (ALIM), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Alimera Sciences Inc  (NASDAQ: ALIM)
 

ALIM's Revenue Growth by Quarter and Year

Alimera Sciences Inc's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

ALIM Revenue (in millions $) FY 2024 FY 2023 FY 2022 FY 2021
4th Quarter December -
3rd Quarter September -
2nd Quarter June 26.17
1st Quarter March 22.66
FY 48.83

ALIMs Annual Revenue
Alimera Sciences Inc's Revenue in the fiscal year 2023 $ 79.92 millions
Alimera Sciences Inc's Revenue in the fiscal year 2022 $ 54.13 millions
Alimera Sciences Inc's Revenue in the fiscal year 2021 $ 59.03 millions
Alimera Sciences Inc's Revenue in the fiscal year 2020 $ 50.82 millions
Alimera Sciences Inc's Revenue in the fiscal year 2019 $ 53.94 millions




ALIM Revenue second quarter 2024 Y/Y Growth Comment
Alimera Sciences Inc reported Revenue rise of 52.95% year on year in the second quarter 2024, to $ 26.17 millions, this is lower than Alimera Sciences Inc's recent average Revenue rise of 74.96%.

Looking into second quarter 2024 results within Major Pharmaceutical Preparations industry 61 other companies have achieved higher Revenue growth. While Alimera Sciences Inc' s Revenue jump of 52.95% ranks overall at the positon no. 312 in the second quarter 2024.


ALIM Revenue ( Y/Y Growth %) 2024
 2023 2022 2021
4th Quarter December - 89.95 % 0.5 % 1.38 %
3rd Quarter September - 66.25 % 11.93 % -2.57 %
2nd Quarter June 52.95 % 17.19 % -32.72 % 116.14 %
1st Quarter March 67.23 % 13.87 % 6.16 % -22.9 %
FY   - 47.64 % -8.29 % -

Financial Statements
Alimera Sciences Inc's second quarter 2024 Revenue $ 26.17 millions ALIM's Income Statement
Alimera Sciences Inc's second quarter 2023 Revenue $ 17.11 millions Quarterly ALIM's Income Statement


ALIM Revenue (Quarter on Quarter Growth %)

 2024
 2023 2022 2021
4th Quarter December - 17.87 % 3.16 % 14.9 %
3rd Quarter September - 32.14 % -6.85 % -44.01 %
2nd Quarter June 15.49 % 26.27 % 22.69 % 93.58 %
1st Quarter March -14.97 % -3.42 % -14.76 % -18.59 %
FY (Year on Year)   - 47.64 % -8.29 % -


Back to ALIM Growth rate Comparisons >> Back to ALIM Growth rate Comparisons >>


Revenue second quarter 2024 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #62
Healthcare Sector #113
Overall #312

Revenue Y/Y Growth Statistics
High Average Low
1123.46 % 74.96 % -32.71 %
(Jun 30 2014)   (Jun 30 2022)
Revenue second quarter 2024 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #62
Healthcare Sector #113
Overall #312
Revenue Y/Y Growth Statistics
High Average Low
1123.46 % 74.96 % -32.71 %
(Jun 30 2014)   (Jun 30 2022)

Revenue by Quarter for the Fiscal Years 2021, 2022, 2023, 2024

Alimera Sciences Inc's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
323.46 % 21.87 % -44 %
(Sep 30 2013)  


ALIM's II. Quarter Q/Q Revenue Comment
Alimera Sciences Inc achieved in the II. Quarter 2024 below company average Revenue jump of 15.49% quarter on quarter, to $ 26.17 millions.

Within Major Pharmaceutical Preparations industry 99 other companies have achieved higher Revenue quarter on quarter growth. While Alimera Sciences Inc's Revenue growth quarter on quarter, overall rank is 772.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #100
Healthcare Sector #200
Overall #772
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #100
Healthcare Sector #200
Overall #772
Revenue Q/Q Growth Statistics
High Average Low
323.46 % 21.87 % -44 %
(Sep 30 2013)  


ALIM's II. Quarter Q/Q Revenue Comment
Alimera Sciences Inc achieved in the II. Quarter 2024 below company average Revenue jump of 15.49% quarter on quarter, to $ 26.17 millions.

Within Major Pharmaceutical Preparations industry 99 other companies have achieved higher Revenue quarter on quarter growth. While Alimera Sciences Inc's Revenue growth quarter on quarter, overall rank is 772.


Alimera Sciences Inc's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2024)		 12 Months Ending
(Mar 31 2024)		 12 Months Ending
(Dec 31 2023)		 12 Months Ending
(Sep 30 2023)		 12 Months Ending
(Jun 30 2023)
Cumulative Revenue 12 Months Ending $ 98.09 $ 89.03 $ 79.92 $ 67.29 $ 58.29
Y / Y Revenue Growth (TTM) 68.28 % 59.62 % 47.64 % 24.48 % 10.78 %
Year on Year Revenue Growth Overall Ranking # 614 # 1835 # 1713 # 920 # 2747
Seqeuential Revenue Change (TTM) 10.17 % 11.4 % 18.76 % 15.45 % 4.5 %
Seq. Revenue Growth (TTM) Overall Ranking # 1568 # 1227 # 1329 # 1980 # 2860


Cumulative Revenue growth Comment
Alimera Sciences Inc saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 68.28% year on year, to $ 98 millions if the fiscal year would have ended in Jun 30 2024.
Alimera Sciences Inc's trailing twelve months Revenue growth was higher than company's average 39.2% and higher than 59.62% growth in Mar 31 2024.
But from twelve months ended Mar 31 2024 rise was beneth at 10.17 % from $89.03 millions achieved in the period from Mar 31 2024 to Jun 30 2023.
We witness drop-off happening, more obvious observing the usual Q/Q TTM historic rise that is stronger at39.2%.
The momentum is even more impressive from twelve months ended Mar 31 2024 exhibited at 10.17 % increase from $89.03 millions in the period from Mar 31 2024 to Jun 30 2023.

In the Healthcare sector 117 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 614, from total ranking in previous quarter at 1835.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 108
Healthcare Sector # 118
Overall # 614

Revenue TTM Y/Y Growth Statistics
High Average Low
166.39 %
 39.2 %
-10.54 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 108
Sector # 298
S&P 500 # 1568
Cumulative Revenue growth Comment
Alimera Sciences Inc saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 68.28% year on year, to $ 98 millions if the fiscal year would have ended in Jun 30 2024.
Alimera Sciences Inc's trailing twelve months Revenue growth was higher than company's average 39.2% and higher than 59.62% growth in Mar 31 2024.
But from twelve months ended Mar 31 2024 rise was beneth at 10.17 % from $89.03 millions achieved in the period from Mar 31 2024 to Jun 30 2023.
We witness drop-off happening, more obvious observing the usual Q/Q TTM historic rise that is stronger at39.2%.
The momentum is even more impressive from twelve months ended Mar 31 2024 exhibited at 10.17 % increase from $89.03 millions in the period from Mar 31 2024 to Jun 30 2023.

In the Healthcare sector 117 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 614, from total ranking in previous quarter at 1835.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 108
Healthcare Sector # 118
Overall # 614

Revenue TTM Y/Y Growth Statistics
High Average Low
166.39 %
39.2 %
-10.54 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 108
Sector # 298
S&P 500 # 1568




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
ALIM's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue jump for the quarter ending Jun 30 2024 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jun 30 2024
Cue Biopharma Inc 92.33%$ 92.330 millions
Arcellx Inc 91.47%$ 91.470 millions
Pmgc Holdings Inc 91.31%$ 91.311 millions
Curevac N v 88.34%$ 88.337 millions
Regen Biopharma Inc 86.68%$ 86.678 millions
Axsome Therapeutics Inc 86.65%$ 86.651 millions
Universal Biosensors Inc 86.62%$ 86.623 millions
Volitionrx Limited82.98%$ 82.977 millions
Innovative Eyewear Inc 81.65%$ 81.654 millions
Adma Biologics Inc 78.34%$ 78.343 millions
Metagenomi Therapeutics Inc 76.48%$ 76.484 millions
Ispecimen inc 76.21%$ 76.211 millions
Axim Biotechnologies Inc 76.04%$ 76.040 millions
Rosecliff Acquisition Corp I75.91%$ 75.912 millions
Castle Biosciences Inc 73.53%$ 73.525 millions
Electrocore Inc 72.88%$ 72.881 millions
Immucell Corporation71.84%$ 71.836 millions
Rxsight Inc 71.12%$ 71.122 millions
Senti Biosciences Holdings Inc 69.37%$ 69.370 millions
Evofem Biosciences Inc 69.24%$ 69.243 millions
Sintx Technologies Inc 69.09%$ 69.094 millions
Sunshine Biopharma Inc 67.30%$ 67.295 millions
Innoviva Inc 61.07%$ 61.070 millions
Trisalus Life Sciences Inc 59.67%$ 59.670 millions
Ataibeckley Inc 58.72%$ 58.721 millions
Procept Biorobotics Corporation58.54%$ 58.537 millions
Natera Inc 58.13%$ 58.127 millions
Provectus Biopharmaceuticals Inc 57.56%$ 57.556 millions
Ligand Pharmaceuticals Incorporated57.52%$ 57.517 millions
Beone Medicines Ltd 56.07%$ 56.072 millions


About Alimera Sciences Inc Revenue Growth Rates (ALIM), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Alimera Sciences Inc (CIK 1267602).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001437749-24-025182
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Alimera Sciences Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.